KalVista Pharmaceuticals (KALV) Reports Q2 Loss of $0.22/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts KALV Hot Sheet
Join SI Premium – FREE
KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.22), versus ($0.50) reported last year. Revenue for the quarter came in at $5.59 million, versus $1.13 million reported last year.
For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber (UBER) Tops Q3 EPS by 2c, Beats on Revenue; Offers Guidance
- SolarEdge Technologies (SEDG) Tops Q3 EPS by 26c ; Offers Guidance
- OPENLANE, Inc. (OPLN) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
